Charles Schwab Investment Management Inc. Grows Stock Position in Relx Plc $RELX

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Relx Plc by 16.5%, owning 167,175 shares worth approximately $8.4 million after acquiring an additional 23,692 shares in the first quarter.
• Following recent performance, Relx's stock opened at $47.80, with a 52-week range between $44.19 and $56.33, and a market capitalization of $87.69 billion.
• Relx recently announced a semi-annual dividend of $0.2634, resulting in a dividend yield of 170.0%, with a payout ratio of 28.49%.

Charles Schwab Investment Management Inc. grew its position in Relx Plc (NYSE:RELX - Free Report) by 16.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 167,175 shares of the technology company's stock after acquiring an additional 23,692 shares during the quarter. Charles Schwab Investment Management Inc.'s holdings in Relx were worth $8,427,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Bleakley Financial Group LLC lifted its position in shares of Relx by 1.5% in the first quarter. Bleakley Financial Group LLC now owns 14,147 shares of the technology company's stock valued at $713,000 after acquiring an additional 207 shares in the last quarter. Bridgewater Advisors Inc. lifted its position in Relx by 2.1% during the first quarter. Bridgewater Advisors Inc. now owns 11,463 shares of the technology company's stock worth $617,000 after buying an additional 238 shares in the last quarter. Kovitz Investment Group Partners LLC lifted its position in Relx by 3.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 8,159 shares of the technology company's stock worth $371,000 after buying an additional 267 shares in the last quarter. Ascent Group LLC lifted its position in Relx by 2.0% during the fourth quarter. Ascent Group LLC now owns 14,024 shares of the technology company's stock worth $637,000 after buying an additional 277 shares in the last quarter. Finally, Portside Wealth Group LLC lifted its position in Relx by 2.5% during the first quarter. Portside Wealth Group LLC now owns 11,710 shares of the technology company's stock worth $590,000 after buying an additional 283 shares in the last quarter. Hedge funds and other institutional investors own 15.02% of the company's stock.

Relx Price Performance

NYSE:RELX opened at $47.80 on Tuesday. Relx Plc has a 52 week low of $44.19 and a 52 week high of $56.33. The company has a quick ratio of 0.42, a current ratio of 0.47 and a debt-to-equity ratio of 2.55. The company has a market capitalization of $87.69 billion, a P/E ratio of 25.70, a P/E/G ratio of 3.16 and a beta of 0.88. The stock's fifty day moving average is $51.58 and its two-hundred day moving average is $51.48.

Relx Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, September 16th. Investors of record on Friday, August 8th will be issued a $0.2634 dividend. This represents a dividend yield of 170.0%. The ex-dividend date is Friday, August 8th. Relx's payout ratio is currently 28.49%.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Relx from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy".

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.